BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 16, 2007
 |  BioCentury  |  Product Development

Adolor chronicles

Adolor chronicles

After hitting a six-year high last September, Adolor (ADLR) began a steady descent when it and partner GlaxoSmithKline (LSE:GSK; GSK) reported mixed Phase III data on their Entereg bowel dysfunction candidate. ADLR took another hit in November when it received a second approvable letter for Entereg asking for 12-month safety data. Those data came out last week, indicating continued cardiovascular safety signals. The partners said they still plan to submit a complete response this quarter to the approvable letter. ADLR has raised more than $500 million in financing since its inception in 1994. Weekly stock price for Adolor (ADLR) tracked against selected events since its IPO in 2000.

A. 11/13/00 - Adolor(ADLR) raises...

Read the full 564 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >